Seminars in Oncology
Volume 29, Issue 4 , Pages 361-369, August 2002

The revised American Joint Committee on Cancer staging system for melanoma☆

On behalf of the AJCC Melanoma Staging Committee: Charles M. Balch, MD, Antonio C. Buzaid, MD, Seng-Jaw Soong, PhD, Michael B. Atkins, MD, Natale Cascinelli, MD, Daniel G. Coit, MD, Irvin D. Fleming, MD, Jeffrey E. Gershenwald, MD, Alan Houghton, Jr, MD, John M. Kirkwood, MD, Kelly M. McMasters, MD, Martin F. Mihm, MD, Donald L. Morton, MD, Douglas S. Reintgen, MD, Merrick I. Ross, MD, Arthur Sober, MD, John A. Thompson, MD, and John F. Thompson, MD.

Abstract 

Substantial progress has been made in identifying the most significant clinical and pathologic characteristics of melanoma that predict for metastasis and survival. The American Joint Committee on Cancer (AJCC) staging system for cutaneous melanoma was recently revised to include these prognostic variables. Major changes in the staging include: (1) melanoma thickness and ulceration but not level of invasion will be used in the T category (except for T1 melanomas); (2) the number of metastatic lymph nodes rather than their gross dimensions and the delineation of clinically occult (ie, “microscopic”) versus clinically apparent (ie, “macroscopic”) nodal metastases will be used in the N category; (3) the site of distant metastases and the presence of elevated serum lactate dehydrogenase (LDH) will be used in the M category; (4) all patients with stage I, II, or III disease will be upstaged when a primary melanoma is ulcerated; (5) satellite metastases around a primary melanoma and in-transit metastases will be merged into a single staging entity that is grouped into stage III disease; and (6) distinct definitions for clinical and pathologic staging will take into account the new staging information gained from intraoperative lymphatic mapping and sentinel node biopsy. Semin Oncol 29:361-369. Copyright 2002, Elsevier Science (USA). All rights reserved.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ Address reprint requests to John A. Thompson, MD, Seattle Cancer Care Alliance, 825 Eastlake Ave E, Mailstop G3-200, Seattle, WA 98109-1023.

PII: S0093-7754(02)50266-9

doi:10.1053/sonc.2002.34115

Seminars in Oncology
Volume 29, Issue 4 , Pages 361-369, August 2002

Article Tools

* Image Usage & Resolution